Kura Oncology Reports Fourth Quarter and Full Year 2022 Financial Results

Posted: February 24, 2023 at 12:14 am

– Phase 1 data for ziftomenib highlighted by 30% CR rate among 20 patients with NPM1-mutant AML treated at recommended Phase 2 dose –

Read the original post:
Kura Oncology Reports Fourth Quarter and Full Year 2022 Financial Results

Related Posts